Physicians join M Health team
Three maternal-fetal medicine specialists have joined University of Minnesota Health.
Stephen A. Contag, MD, completed his residency at Mayo Clinic and a fellowship in maternal-fetal medicine at Wake Forest University. His clinical focus is prenatal ultrasound of the fetal central nervous system and management of maternal obstetrical complications.
Sarah N. Cross, MD, a specialist in diagnosis of fetal anomalies and care for women with complex medical conditions, also joins the team. Following her residency at Yale School of Medicine, Cross completed 2 fellowships (ultrasound and maternal-fetal medicine) at that institution.
Cresta W. Jones, MD, offers a clinical focus on substanc2use disorders in pregnancy and hypertension in pregnancy. She completed her residency in obstetrics and gynecology and her fellowship in maternal-fetal medicine at the University of Vermont College of Medicine. During her training, she worked in a program treating women with opioid use disorders during pregnancy.
Clinical trial on fetal heart block opens
A multicenter trial on early identification of fetal heart block is enrolling pregnant patients with SSA or SSA and SSB antibodies prior to 19-weeks gestation at its University of Minnesota study site. SSA/SSB antibodies damage or destroy the electrical connection between the heart’s atria and ventricles. Researchers seek to determine if at-home Doppler devices are successful at identifying fetuses with heart rate irregularities prior to their developing complete heart block. University of Minnesota Health specialist Katherine Jacobs, DO, is a Minnesota site researcher. To enroll a patient, contact 612-273-2223.
Study seeks to inform opioid prescription practices
A 1-year multisite study seeks to provide additional insight into the amount of opioids used by patients after cesarean section or vaginal birth, with the goal of reducing any overprescribing. Two recent small studies found that after cesarean section, women used only about half of the opioids prescribed (mean use was 20 tabs out of 40), leaving many tablets unused or available for illicit purposes. The goal of this larger-scale study is to validate the earlier findings on amounts prescribed. Cresta W. Jones, MD, serves as an investigator.
With the rise in opioid abuse, an increasing number of infants are born with neonatal abstinence syndrome. M Health specialists provide insight into the latest care approaches for these patients and their mothers.Continue reading
A pregnant patient diagnosed with opioid use disorder is administered medication-assisted therapy. The infant upon delivery requires further monitoring, however, demonstrates no signs of neonatal abstinence syndrome.Continue reading